Trials / Completed
CompletedNCT00998309
Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)
Zithromax-SR 2g, Special Investigation For Skin And Soft Tissue Infection, Sexually-Transmitted Infection, And Infection Of The Oral (Regulatory Post Marketing Commitment Plan)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 502 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To collect the efficacy and safety information of Zithromax-SR related to their appropriate use in daily practice.
Detailed description
All the patients whom an investigator prescribes the first Azithromycin SR should be registered within 14 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azithromycin SR | Zithromax SR 2g, taking once for treatment. |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2009-10-20
- Last updated
- 2012-05-01
- Results posted
- 2012-05-01
Source: ClinicalTrials.gov record NCT00998309. Inclusion in this directory is not an endorsement.